

BIBLIOGRAPHY

- Amodio, F., Caiazza, M., Fimiani, F., Calabrò, P., & Limongelli, G. (2021). MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. *Cardiogenetics* 11 : 230–254. Available at: <https://doi.org/10.3390/cardiogenetics11040023>
- Brindel, A., Althakfi, W., Barritault, M., Watkin, E., Maury, J.M., Bringuier, P.P., *et al.* (2020). Uncommon EGFR mutations in lung adenocarcinoma: Features and response to tyrosine kinase inhibitors. *J. Thorac. Dis.* 12 : 4643–4650. Available at: <https://doi.org/10.21037/jtd-19-3790>
- Brockmoeller, S., Young, C., Lee, J., Arends, M.J., Wilkins, B.S., Thomas, G.J., *et al.* (2019). Survey of UK histopathology consultants' attitudes towards academic and molecular pathology. *J. Clin. Pathol.* 72 : 399–405. Available at: <https://doi.org/10.1136/jclinpath-2018-205568>
- Cagle, P.T. (2019). *Pulmonary Pathology*, 3rd ed. Wolters Kluwer.
- Canberk, S., & Engels, M. (2021). Cytology samples and molecular biomarker testing in lung cancer—advantages and challenges. *Virchows Arch.* 478 : 45–57. Available at: <https://doi.org/10.1007/s00428-020-02995-2>
- Cancer research UK (2024). Lung cancer incidence statistics | Cancer Research UK [WWW Document]. URL <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence#heading-One> (accessed 7.25.25).
- Castañeda-González, J.P., Chaves, J.J., & Parra-Medina, R. (2022). Multiple mutations in the EGFR gene in lung cancer: a systematic review. *Transl. Lung Cancer Res.* 11 : 2148–2163. Available at: <https://doi.org/10.21037/tlcr-22-235>
- Cooper, W.A., Chou, T.-Y., MacMahon, H., Warth, A., Yoshizawa, A., & Chang, J.C. (2021a). Invasive mucinous adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/29> (accessed 5.8.25).
- Cooper, W.A., Ladanyi, M., Van Schil, P.E.Y.V.S., Scagliotti, G. V., Bubendorf, L., Kadota, K., *et al.* (2021b). Invasive non-mucinous adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/23> (accessed 5.8.25).
- Dahlan, M.S. (2009). Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Salemba Medika.
- Dao, T. Van, Dinh, V.L., Doan, T.V., & Phuong, T. Le (2025). Prevalence of EGFR Mutations in Vietnamese Patients with Resected Early Stage Non-Small Cell Lung Cancer: EARLY-EGFR Study. *Lung Cancer Targets Ther.* 16 : 39–49. Available at: <https://doi.org/10.2147/LCTT.S494554>
- Dorta-Suárez, M., de Miguel, M., Amor-Carro, O., Calderón, J.M., González-Ortega, Mc.C., & Rodríguez-Abreu, D. (2024). The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives. *Cancer Treat. Rev.* 124. Available at:

<https://doi.org/10.1016/j.ctrv.2023.102671>

- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D.M., Piñeros, M., Znaor, A., *et al.* (2024). Cancer statistics for the year 2020: An overview. *Int. J. Cancer* 149 : 778–789. Available at: <https://doi.org/10.1002/ijc.33588>
- Florczuk, M., Szpechcinski, A., & Chorostowska-Wynimko, J. (2017). miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. *Target. Oncol.* 12 : 179–200. Available at: <https://doi.org/10.1007/s11523-017-0478-5>
- Gazdar, A.F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene* 28 : S24–S31. Available at: <https://doi.org/10.1038/onc.2009.198>
- Geisinger, K., Bubendorf, L., Kholova, I., & Michael, C.W. (2022). WHO Reporting System for Lung Cytopathology // Chapter 7: Diagnostic category: Malignant // Specific malignant lesions // Non-small cell carcinomas // Adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/48/85> (accessed 5.8.25).
- Global Adult Tobacco Survey (GATS) (2023). Global Adult Tobacco Survey (GATS) Indonesia Report 2021. Jakarta PP - Jakarta : World Health Organization. Country Office for Indonesia.
- Han, Z., Zhu, Z., Zhang, Z., Dong, J., Yang, X., & Feng, J. (2025). Global burden of lung cancer in adolescents and adults aged 15–45: analysis of the global burden of disease study (1990–2021). *Front. Med.* 12 : 1–10. Available at: <https://doi.org/10.3389/fmed.2025.1600662>
- Hanafi, A.R. (2020). Ekspresi serum miR-34 dan miR-222 sebagai petanda biologi molekular prognosis pada kanker paru karsinoma bukan sel kecil (KPKBSK) stage lanjut di indonesia. Universitas Gadjah Mada.
- Harrison, P.T., Vyse, S., & Huang, P.H. (2020). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. *Semin. Cancer Biol.* 61 : 167–179. Available at: <https://doi.org/10.1016/j.semcancer.2019.09.015>
- Herbst, R.S. (2004). Review of epidermal growth factor receptor biology. *Int. J. Radiat. Oncol. Biol. Phys.* 59 : S21–S26. Available at: <https://doi.org/10.1016/j.ijrobp.2003.11.041>
- Jain, D., Asamura, H., MacMahon, H., Nakatani, Y., & Cardona, A.F. (2021a). Fetal adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/32> (accessed 5.8.25).
- Jain, D., Schil, P.E.Y. Van, MacMahon, H., Pelosi, G., Riely, G., & Rusch, V.W. (2021b). Colloid adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/31> (accessed 5.8.25).
- Jain, D., Soares, F.A., MacMahon, H., Nakatani, Y., & Zhang, J. (2021c). Enteric-type adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/33> (accessed 5.8.25).
- Jin, X., Chen, Y., Chen, H., Fei, S., Chen, D., Cai, X., *et al.* (2017). Evaluation of

- tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. *Clin. Cancer Res.* 23 : 5311–5319. Available at: <https://doi.org/10.1158/1078-0432.CCR-17-0577>
- John, T., Taylor, A., Wang, H., Eichinger, C., Freeman, C., & Ahn, M.J. (2022). Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. *Cancer Epidemiol.* 76 : 102080. Available at: <https://doi.org/10.1016/j.canep.2021.102080>
- Kementerian Kesehatan Republik Indonesia (2023). Pedoman Nasional Pelayanan Kedokteran Tatalaksana Kanker Paru.
- Khaddour, K., Jonna, S., Deneka, A., Patel, J.D., Abazeed, M.E., Golemis, E., *et al.* (2021). Targeting the epidermal growth factor receptor in egfr-mutated lung cancer: Current and emerging therapies. *Cancers (Basel)*. 13 : 1–24. Available at: <https://doi.org/10.3390/cancers13133164>
- Kour, O., & Garg, M. (2021). The genomic landscape of lung adenocarcinoma—insights towards personalized medicine. *Proc. Indian Natl. Sci. Acad.* 87 : 562–577. Available at: <https://doi.org/10.1007/s43538-021-00054-1>
- Lababede, O., & Meziane, M.A. (2018). The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. *Oncologist* 23 : 844–848. Available at: <https://doi.org/10.1634/theoncologist.2017-0659>
- Lam, D.C.L., Liam, C.K., Andarini, S., Park, S., Tan, D.S.W., Singh, N., *et al.* (2023). Lung Cancer Screening in Asia: An Expert Consensus Report. *J. Thorac. Oncol.* 18 : 1303–1322. Available at: <https://doi.org/10.1016/j.jtho.2023.06.014>
- Lee, H.Y., Lee, K.S., Han, J., Kim, B.T., Cho, Y.S., Shim, Y.M., *et al.* (2009). Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. *Lung Cancer* 65 : 170–175. Available at: <https://doi.org/10.1016/j.lungcan.2008.11.009>
- Lee, R., Feinbaum, R., & Ambros, V. (1993). The *C. elegans* Heterochronic Gene *lin-4* Encodes Small RNAs with Antisense Complementarity to *lin-14*. *Cell* 116 : 843–854.
- Liu, C., Wang, Z., Liu, Q., Wu, G., Chu, C., Li, L., *et al.* (2022). Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors. *Clin. Transl. Oncol.* 24 : 1975–1985. Available at: <https://doi.org/10.1007/s12094-022-02854-3>
- Livak, K.J., & Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* 25 : 402–408. Available at: <https://doi.org/10.1006/meth.2001.1262>
- Ma, Y., Bao, C., Kong, R., Xing, X., Zhang, Y., Li, S., *et al.* (2015). MicroRNA-361-5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non-small cell lung cancer. *Mol. Med. Rep.* 12 : 7367–7373. Available at: <https://doi.org/10.3892/mmr.2015.4411>
- Mancuso_Cancer Cytopathology - 2016 - Mancuso - Prognostic impact of a 3-MicroRNA signature in cytological samples of small cell.pdf (n.d.).
- Matsubara, D., Kyuichi Kadota, MacMahon, H., & Yokose, T. (2021). Minimally

- invasive adenocarcinoma of the lung [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/35> (accessed 5.8.25).
- Melosky, B., Kambartel, K., Häntschel, M., Bennetts, M., Nickens, D.J., Brinkmann, J., *et al.* (2022). Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. *Mol. Diagnosis Ther.* 26 : 7–18. Available at: <https://doi.org/10.1007/s40291-021-00563-1>
- Moreira, A.L., & Haba Reiji (2022). WHO Reporting System for Lung Cytopathology // Chapter 6: Diagnostic category: Suspicious for malignancy [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/48/68> (accessed 5.8.25).
- Myers, David J. & Wallen, J.M. (2023). Lung Adenocarcinoma [WWW Document]. URL <https://www.ncbi.nlm.nih.gov/books/NBK519578/> (accessed 11.11.24).
- Nee-Estuye-Evangelista, C.K., Andal, J.J., & Ang, D. (2018). Frequency of Epidermal Growth Factor Receptor Mutations among Filipino Patients with Non-small Cell Lung Carcinoma in a Private Tertiary Care Setting. *Philipp. J. Pathol.* 3 : 6–11. Available at: <https://doi.org/10.21141/pjp.2018.002>
- Njoto, E.N., Kedokteran, F., Teknologi, I., Nopember, S., Pamungkas, Y., Kedokteran, F., *et al.* (2024). Jurnal Penyakit Dalam Indonesia Analisis Prediktif Mutasi EGFR pada Adenokarsinoma Paru Menggunakan Pendekatan Pembelajaran Mesin Analisis Prediktif Mutasi EGFR pada Adenokarsinoma Paru Menggunakan 11. Available at: <https://doi.org/10.7454/jpdi.v11i4.1641>
- Noronha, V., Budukh, A., Chaturvedi, P., Anne, S., Punjabi, A., Bhaskar, M., *et al.* (2024). Uniqueness of lung cancer in Southeast Asia. *Lancet Reg. Heal. - Southeast Asia* 27 : 100430. Available at: <https://doi.org/10.1016/j.lansea.2024.100430>
- North, C.M., & Christiani, D.C. (2013). Women and Lung Cancer: What is New? *Semin. Thorac. Cardiovasc. Surg.* 25 : 87–94. Available at: <https://doi.org/10.1053/j.semtevs.2013.05.002>
- Othman, N., & Nagoor, N.H. (2018). Overexpression of miR-361-5p plays an oncogenic role in human lung adenocarcinoma through the regulation of SMAD2. *Int. J. Oncol.* Available at: <https://doi.org/10.3892/ijo.2018.4602>
- Passaro, A., Mok, T., Peters, S., Popat, S., Ahn, M.J., & de Marinis, F. (2021). Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. *J. Thorac. Oncol.* 16 : 764–773. Available at: <https://doi.org/10.1016/j.jtho.2020.12.002>
- Raez, L.E., Baca, Y., Ribeiro, J.R., Nieva, J.J., Mamdani, H., Lopes, G., *et al.* (2025). Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC). *Expert Rev. Anticancer Ther.* 25 : 711–718. Available at: <https://doi.org/10.1080/14737140.2025.2491648>; JOURNAL: JOURNAL: IER Y20

- Rajadurai, P., Yap, N.Y., Mohamed Yousoof, S.B., & Cheah, Y.K. (2023). Mutational Profiling of Lung Cancer Using Next Generation Sequencing: A Malaysian Real-World Clinical Diagnostic Experience. *J. Mol. Pathol.* 4 : 31–43. Available at: <https://doi.org/10.3390/jmp4010004>
- Raniszevska, A., Kwiecień, I., Rutkowska, E., Rzepecki, P., & Domagała-Kulawik, J. (2021). Lung cancer stem cells—origin, diagnostic techniques and perspective for therapies. *Cancers (Basel)*. 13 : 1–17. Available at: <https://doi.org/10.3390/cancers13122996>
- Review, N. (2023). Non-small cell lung cancer (NSCLC) 8 : 10–14.
- Riely, G.J., Wood, D.E., Ettinger, D.S., Aisner, D.L., Akerley, W., Bauman, J.R., *et al.* (2024). Non-Small Cell Lung Cancer, Version 4.2024. *JNCCN J. Natl. Compr. Cancer Netw.* 22 : 249–274. Available at: <https://doi.org/10.6004/jnccn.2204.0023>
- Ryan Feraldy Haroen, Paranita Ferronika, Rita Cempaka, Indrawati, Bening Rahimi Titisari, Vincent Lau, *et al.* (2024). EGFR mutation based on lung laterality in adenocarcinoma type of non-small cell lung cancer. *Indones. J. Biomed. Clin. Sci.* 56 : 217–226. Available at: <https://doi.org/10.22146/inajbcs.v56i3.15943>
- Sakurada, A., Shepherd, F.A., & Tsao, M.S. (2006). Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations. *Clin. Lung Cancer* 7 : S138–S144. Available at: <https://doi.org/10.3816/CLC.2006.s.005>
- Schmitt, F.C., Bubendorf, L., Canberk, S., Chandra, A., Cree, I.A., Engels, M., *et al.* (2023). The World Health Organization Reporting System for Lung Cytopathology. *Acta Cytol.* 67 : 80–91. Available at: <https://doi.org/10.1159/000527580>
- Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025). Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). *Int. J. Mol. Sci.* 26. Available at: <https://doi.org/10.3390/ijms26052049>
- Thandra, K.C., Barsouk, Adam, Saginala, K., Aluru, J.S., & Barsouk, Alexander (2021). Epidemiology of lung cancer. *Contemp. Oncol.* 45–52. Available at: <https://doi.org/https://doi.org/10.5114/wo.2021.103829> Epidemiology
- Tomic, K., Krpina, K., Baticic, L., Samarzija, M., & Vranic, S. (2024). Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. *J. Drug Target.* 32 : 499–509. Available at: <https://doi.org/10.1080/1061186X.2024.2332733>
- Trinh, J.Q., & Abughanimeh, O. (2024). Current management of uncommon EGFR mutations in non-small cell lung cancer. *Curr. Probl. Cancer* 49 : 101064. Available at: <https://doi.org/10.1016/j.currproblcancer.2024.101064>
- Tsao, M.S., Znaor, A., Travis, W.D., Yatabe, Y., Borczuk, A.C., Kerr, K.M., *et al.* (2021). Tumours of the lung: Introduction [WWW Document]. URL <https://tumourclassification.iarc.who.int/chaptercontent/35/2> (accessed 5.8.25).
- Tu, H.Y., Ke, E.E., Yang, J.J., Sun, Y.L., Yan, H.H., Zheng, M.Y., *et al.* (2017). A comprehensive review of uncommon EGFR mutations in patients with non-

- small cell lung cancer. *Lung Cancer* 114 : 96–102. Available at: <https://doi.org/10.1016/j.lungcan.2017.11.005>
- Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., *et al.* (2012). Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung Cancer* 78 : 207–211. Available at: <https://doi.org/10.1016/j.lungcan.2012.09.006>
- WC Chan, L., F Wang, F., & CS Cho, W. (2012). Genomic Sequence Analysis of EGFR Regulation by MicroRNAs in Lung Cancer. *Curr. Top. Med. Chem.* 12 : 920–926. Available at: <https://doi.org/10.2174/156802612800166747>
- WHO Classification of Tumours Editorial Board. (2021). Thoracic tumours, in: *WHO Classification of Tumours*. Lyon: International Agency for Research on Cancer.
- Wilson, R.T. (2021). Update on cytology samples for the use of molecular pathology and other ancillary tests in the move towards next-generation sequencing. *Diagnostic Histopathol.* 27 : 459–466. Available at: <https://doi.org/10.1016/j.mpdhp.2021.08.005>
- Wu, K.L., Tsai, Y.M., Lien, C.T., Kuo, P.L., & Hung, J.Y. (2019). The roles of microRNA in lung cancer. *Int. J. Mol. Sci.* 20 : 1–25. Available at: <https://doi.org/10.3390/ijms20071611>
- Xia, J., Luo, M., Dai, L., Wang, Liusheng, Wang, Limin, & Zhu, J. (2021). Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer. *J. Clin. Lab. Anal.* 35 : 1–12. Available at: <https://doi.org/10.1002/jcla.23743>
- Xu, J., Tian, L., Qi, W., Lv, Q., & Wang, T. (2024). Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments. *Am. J. Clin. Oncol. Cancer Clin. Trials* 47 : 291–303. Available at: <https://doi.org/10.1097/COC.0000000000001088>
- Zhang, Y.L., Yuan, J.Q., Wang, K.F., Fu, X.H., Han, X.R., Threapleton, D., *et al.* (2016). The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. *Oncotarget* 7 : 78985–78993. Available at: <https://doi.org/10.18632/oncotarget.12587>